- NIA statement on FDA approval of aducanumab for Alzheimer’s disease— NIA Director Richard J. Hodes, M.D., reflects on a milestone in Alzheimer’s research: the first approved treatment to slow progression of the disease.
- Mouse study suggests that repairing brain protein production could counteract Alzheimer’s disease — A new study, funded in part by NIA, found that mice with cognitive problems did better on memory-associated behavior tests when protein production was restored in the brain.
- Nearly 14% of older adults with dementia are prescribed a combination of medicines affecting the central nervous system — NIA-supported study is the first to examine the number of adults with dementia who live in the community, not in nursing homes, and take multiple medications that target the brain and spinal cord. Taking combinations of these drugs can lead to an increased risk of falling, breathing issues, and heart problems.